Eli Lilly and Company (LLY)
FDA Nudge Sends Pharma Stock to Fresh Record Highs
Shares of Eli Lilly And Co (NYSE:LLY) are enjoying a 2.3% surge this morning, last seen trading near $885.10 on the back of news that the Food and Drug Administration (FDA) panel unanimously approved the pharmaceutical company's Alzheimer's drug, donanemab.
Eli Lilly Hits an All-Time High: Is the Soaring Pharma Stock Still a Buy?
Lilly's current product lineup includes multiple growth drivers, including Mounjaro and Zepbound. The company's pipeline also features promising candidates, with two currently awaiting regulatory approvals.
Eli Lilly Stock Gains After FDA Advisors Recommend Alzheimer's Drug Donanemab
Eli Lilly (LLY) shares gained more than 2% in extended trading on Monday after a panel of independent advisors to the Food and Drug Administration (FDA) unanimously recommended the pharmaceutical giant's Alzheimer's drug donanemab, increasing the likelihood of its approval in the U.S. later this year.
2 Biotech Stocks For Your June 2024 Watchlist
Biotech stocks to check out in the stock market now.
Eli Lilly and Company (LLY) Goldman Sachs 45th Annual Global Healthcare Conference
Eli Lilly and Company (NYSE:LLY ) Goldman Sachs 45th Annual Global Healthcare Conference June 10, 2024 4:00 PM ET Company Participants Patrik Jonsson - Executive Vice President, President of Lilly Diabetes and Obesity and Lilly USA Conference Call Participants Chris Shibutani - Goldman Sachs Chris Shibutani Okay, let's get underway here for the Lilly session. One of the most and highly anticipated and we're so appreciative of the entire Lilly team that's here.
FDA Panel Unanimously Recommends Eli Lilly's Alzheimer's Drug
A Food and Drug Administration advisory panel unanimously voted Monday to recommend Eli Lilly's Alzheimer's drug donanemab for approval, according to multiple outlets, sending the pharmaceutical company's shares up modestly in after-hours trading and making the treatment's final approval more likely.
Eli Lilly exec expects obesity pill data in April 2025
Data from Eli Lilly's late stage trial on experimental obesity pill orforglipron is expected in April 2025, a top Eli Lilly executive said on Monday.
Eli Lilly's Alzheimer's drug gets backing from FDA advisers
Eli Lilly & Co.'s experimental Alzheimer's drug donanemab on Monday moved a step closer to U.S. regulatory approval as it won support from an independent panel of advisers to the Food and Drug Administration.
Eli Lilly exec says seeing out of pocket payments for obesity drug in US
A top Eli Lilly executive said on Monday that more patients are paying the full list price of its obesity drug Zepbound than those who had paid for its predecessor Mounjaro.
FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approval
A panel of independent advisors to the FDA recommended Eli Lilly's Alzheimer's drug donanemab, paving the way for the treatment to receive full approval in the U.S. later this year. If approved, Eli Lilly's drug would become the second Alzheimer's drug of its kind to enter the U.S. market after another treatment called Leqembi from Biogen and Eisai.
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
US FDA advisers to review Eli Lilly Alzheimer's drug
An independent advisory panel to the U.S. Food and Drug Administration will vote later on Monday on the safety and effectiveness of Eli Lilly's experimental Alzheimer's drug donanemab.
